Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Eduardo Fernandez, MD

Advertisement

Articles by Eduardo Fernandez, MD

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

ByChirag Shah, MD,Kevin Stephans, MD,Aditya Juloori, MD,Andrew Vassil, MD,Constantine Mantz, MD,Alvaro Martinez, MD,Frank Vicini, MD,Eduardo Fernandez, MD,Rahul D. Tendulkar, MD,Steven E. Finkelstein, MD
June 20th 2016

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Advertisement

Latest Updated Articles

  • Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer
    Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

    June 20th 2016



Advertisement
Advertisement

Trending on OncLive

1

FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma

2

Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

3

Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma

4

Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer

5

Dr Rodriguez on the Rationale for Testing LAG-3/PD-1 Dual Blockade in Nonsquamous NSCLC

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us